GO:0141039 phosphatidylinositol 3-kinase inhibitor activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0141039 phosphatidylinositol 3-kinase inhibitor activity describes the molecular function of binding to and decreasing the activity of a phosphatidylinositol 3-kinase (PI3K).
• Small-molecule PI3K inhibitors such as wortmannin, PX-866, NVP-BKM120 and ZSTK474 are experimental tools that block PI3K signaling and are studied in cancer and other diseases.
• PI3K inhibition can induce senescent-like growth arrest in human diploid fibroblasts, linking this activity to cell-cycle control.
• PI3K inhibitor activity regulates diverse processes including mast cell ion channel activity, calcium-dependent Akt activation in nerve terminals, and microenvironment-derived survival signals in leukemia cells.
• CRISPR knockout, point-mutation, knock-in and overexpression models enable causal testing of genes that mediate or respond to PI3K inhibitor activity.
• EDITGENE provides custom cell models and CRISPR library screening to study phosphatidylinositol 3-kinase inhibitor activity in disease-relevant contexts.
Description
Phosphatidylinositol 3-kinase inhibitor activity (GO:0141039) is a molecular function defined by binding to and decreasing the activity of a phosphatidylinositol 3-kinase (PI3K). PI3K enzymes phosphorylate phosphoinositides to generate lipid second messengers that recruit and activate downstream effectors such as Akt, thereby controlling cell growth, survival, metabolism and ion transport. Because PI3K signaling is frequently dysregulated in cancer and other diseases, molecules that inhibit PI3K are both important research tools and candidate therapeutics. Experimentally, PI3K inhibitor activity is studied using small molecules such as wortmannin, PX-866, NVP-BKM120 and ZSTK474, which bind PI3K and reduce its catalytic output. These inhibitors have been used to show that PI3K activity regulates mast cell ion channel function, couples localized calcium influx to Akt activation in central nerve terminals, and drives survival signals in chronic lymphocytic leukemia cells. In human diploid fibroblasts, a PI3K inhibitor induces a senescent-like growth arrest, demonstrating that this activity impinges on cell-cycle control. For researchers, GO:0141039 provides a precise annotation for any gene product or chemical entity that directly binds and inhibits PI3K. Understanding this function is essential for interpreting experiments that use PI3K inhibitors, for designing CRISPR models of inhibitor-sensitive pathways, and for developing therapies that target PI3K-dependent diseases.
phosphatidylinositol 3-kinase inhibitor activity At A Glance
| GO ID | GO:0141039 |
|---|---|
| GO term | phosphatidylinositol 3-kinase inhibitor activity |
| Ontology | molecular_function |
| Synonym | None listed in QuickGO |
| Major function | Binds to and decreases the activity of a phosphatidylinositol 3-kinase (PI3K) |
| Representative inhibitors | Wortmannin, PX-866, NVP-BKM120, ZSTK474 |
| Cellular context | Regulates ion channels, calcium signaling, Akt activation and cell survival |
| Disease relevance | Cancer resistance, leukemia microenvironment signaling, growth arrest |
What Is GO:0141039?
GO:0141039 phosphatidylinositol 3-kinase inhibitor activity is a molecular function term describing the ability of a gene product or chemical agent to bind to a phosphatidylinositol 3-kinase (PI3K) and decrease its enzymatic activity. This function is distinct from merely being a substrate or downstream effector of PI3K; it requires a direct inhibitory interaction that reduces PI3K-mediated lipid phosphorylation and subsequent signaling.
Why Is phosphatidylinositol 3-kinase inhibitor activity Important in Cell Biology?
Phosphatidylinositol 3-kinase inhibitor activity is important because PI3K signaling is a central node in cell growth, survival and metabolism, and its inhibition can reverse resistance to targeted therapies, block survival signals from the tumor microenvironment, and induce growth arrest in normal and malignant cells. Small-molecule PI3K inhibitors are widely used to dissect these pathways, and understanding the molecular function of inhibitor activity helps researchers interpret pharmacological experiments and design genetic models that mimic or counteract PI3K inhibition.
• PI3K inhibitor activity is a defined molecular function that directly reduces PI3K catalytic output.
• It is experimentally tractable using well-characterized small molecules such as wortmannin, PX-866, NVP-BKM120 and ZSTK474.
• PI3K inhibition can overcome resistance to EGFR inhibitors in non-small cell lung cancer xenografts.
• It can counteract microenvironment-derived survival signals in chronic lymphocytic leukemia cells via the Akt/FoxO3a/Bim axis.
• PI3K inhibitor activity induces senescent-like growth arrest in human diploid fibroblasts.
• It regulates mast cell ion channel activity, linking lipid signaling to ion transport.
• It couples localized calcium influx to Akt activation in central nerve terminals.
• It is a target for drug discovery, as shown by the identification and optimization of ZSTK474 analogues.
• CRISPR models of PI3K pathway genes can test causality of inhibitor responses.
• Understanding this activity supports development of combination therapies in cancer and other diseases.
Molecular Mechanism of phosphatidylinositol 3-kinase inhibitor activity
Binding to PI3K and inhibition of lipid kinase activity
In simple terms: The inhibitor sticks to PI3K and stops it from working.
Phosphatidylinositol 3-kinase inhibitor activity begins with binding of the inhibitor to PI3K, which decreases the enzyme's ability to phosphorylate phosphoinositides. This inhibition reduces production of lipid second messengers such as PIP3, thereby limiting downstream signaling. Small molecules like wortmannin and ZSTK474 exemplify this direct binding and inhibition.
Downstream effects on Akt activation
In simple terms: When PI3K is blocked, the Akt survival signal goes down.
Inhibition of PI3K decreases Akt activation, as shown in central nerve terminals where PI3K couples localized calcium influx to Akt. In chronic lymphocytic leukemia cells, PI3K inhibition regulates the Akt/FoxO3a/Bim axis, reducing survival signals derived from the microenvironment. These effects link PI3K inhibitor activity to apoptosis and cell survival decisions.
Regulation of ion channels and calcium signaling
In simple terms: PI3K inhibitors can change how ions move in and out of cells.
PI3K inhibitor activity regulates mast cell ion channel activity, indicating that PI3K lipid products modulate ion transport. In nerve terminals, PI3K couples local calcium influx to Akt activation, showing that inhibitor activity can disrupt calcium-dependent signaling. These findings expand the physiological roles of PI3K inhibition beyond classical growth factor signaling.
Cell-cycle arrest and senescence
In simple terms: Blocking PI3K can make cells stop dividing and look aged.
A PI3K inhibitor induces a senescent-like growth arrest in human diploid fibroblasts, demonstrating that PI3K inhibitor activity can trigger durable cell-cycle exit. This phenotype is relevant to understanding how PI3K inhibition affects normal cells and to designing cancer therapies that exploit senescence.
Overcoming therapeutic resistance
In simple terms: PI3K inhibitors can make resistant cancer cells respond again.
The PI3K inhibitor PX-866 overcomes resistance to the EGFR inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts. Similarly, NVP-BKM120 overcomes microenvironment-derived resistance signals in chronic lymphocytic leukemia cells. These studies show that PI3K inhibitor activity can be therapeutically leveraged in combination regimens.
Key Genes Involved in GO:0141039 phosphatidylinositol 3-kinase inhibitor activity
The following genes and proteins are central to phosphatidylinositol 3-kinase inhibitor activity, either as direct targets of inhibition or as key downstream effectors and regulators.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PIK3CA | Catalytic subunit of class I PI3K; direct target of inhibitors | Mutations common in cancer; tested with PI3K inhibitors |
| PIK3CB | Catalytic subunit of PI3K beta isoform | Isoform-selective inhibitor studies |
| PIK3CD | Catalytic subunit of PI3K delta isoform | Inhibitor development for leukemia and immune cells |
| PIK3CG | Catalytic subunit of PI3K gamma isoform | Inhibitor studies in inflammation and cancer |
| PIK3R1 | Regulatory subunit of PI3K | Modulates inhibitor sensitivity |
| AKT1 | Downstream kinase activated by PI3K | Readout of PI3K inhibitor activity |
| AKT2 | Downstream kinase isoform | Context-dependent survival signaling |
| FOXO3A | Transcription factor inhibited by Akt | Mediates PI3K inhibitor effects on Bim |
| BCL2L11 (BIM) | Pro-apoptotic BH3-only protein | Upregulated by PI3K inhibition |
| EGFR | Receptor tyrosine kinase upstream of PI3K | Resistance overcome by PX-866 |
| PTEN | Lipid phosphatase that opposes PI3K | Loss sensitizes to PI3K inhibitors |
| MTOR | Downstream kinase in PI3K pathway | Combination targeting with PI3K inhibitors |
| RPS6KB1 | mTOR effector kinase | Readout of PI3K/mTOR inhibition |
| CALM1 | Calmodulin; calcium signaling component | Links calcium to PI3K/Akt in nerve terminals |
| KCNN4 | Calcium-activated potassium channel | Regulated by PI3K in mast cells |
| CBR1 | Carbonyl reductase; metabolizes wortmannin | Influences wortmannin potency |
| ZSTK474 target (PI3K) | Pan-PI3K inhibitor binding | Tool compound for PI3K inhibition |
How Is phosphatidylinositol 3-kinase inhibitor activity Regulated?
Phosphatidylinositol 3-kinase inhibitor activity is regulated at multiple levels. The expression and activity of PI3K isoforms determine sensitivity to inhibitors. Upstream receptor tyrosine kinases such as EGFR can drive PI3K signaling and confer resistance to inhibitors, which can be overcome by direct PI3K inhibition. The lipid phosphatase PTEN opposes PI3K activity, and loss of PTEN can sensitize cells to PI3K inhibitors. In leukemia cells, microenvironment-derived signals modulate the response to PI3K inhibitors through the Akt/FoxO3a/Bim axis. Additionally, drug metabolism can affect inhibitor activity; for example, wortmannin is metabolized by carbonyl reductase, which can influence its potency.
phosphatidylinositol 3-kinase inhibitor activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PIK3CA | Non-small cell lung cancer resistance | A-549 xenograft with PX-866 treatment |
| PIK3CD | Chronic lymphocytic leukemia | Primary CLL cells with NVP-BKM120 |
| PTEN | Cancer predisposition and inhibitor sensitivity | PTEN-knockout cell lines |
| EGFR | EGFR-mutant lung cancer | Gefitinib-resistant xenografts |
| AKT1 | Survival signaling in leukemia | Akt phosphorylation readouts |
Cancer resistance and combination therapy
PI3K inhibitor activity is directly relevant to overcoming resistance to targeted therapies. PX-866, a PI3K inhibitor, overcomes resistance to the EGFR inhibitor gefitinib in A-549 non-small cell lung cancer xenografts. This suggests that combining PI3K inhibitors with receptor tyrosine kinase inhibitors may be beneficial in resistant tumors. ZSTK474 and its analogues have been developed as anticancer PI3K inhibitors, highlighting the therapeutic potential of this activity.
Chronic lymphocytic leukemia and microenvironment signaling
In chronic lymphocytic leukemia cells, the PI3K inhibitor NVP-BKM120 overcomes resistance signals derived from the microenvironment by regulating the Akt/FoxO3a/Bim axis. This demonstrates that PI3K inhibitor activity can disrupt survival cues from the tumor microenvironment and promote apoptosis. These findings support clinical investigation of PI3K inhibitors in hematological malignancies.
Cellular senescence and growth arrest
A PI3K inhibitor induces a senescent-like growth arrest in human diploid fibroblasts, linking PI3K inhibitor activity to cell-cycle control and aging-related phenotypes. This has implications for understanding how PI3K inhibition affects normal tissues and for designing therapies that exploit senescence.
Ion channel and neurological signaling
PI3K inhibitor activity regulates mast cell ion channel activity, indicating a role in immune cell function. In central nerve terminals, PI3K couples localized calcium influx to Akt activation, suggesting that PI3K inhibitors can modulate neuronal signaling. These findings broaden the disease relevance of PI3K inhibition beyond cancer.
From phosphatidylinositol 3-kinase inhibitor activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate gene mimic PI3K inhibition? | CRISPR knockout cell lines |
| Does a point mutation in PI3K alter inhibitor sensitivity? | CRISPR point-mutation knock-in |
| Can a tagged PI3K allele report inhibitor binding? | Knock-in of epitope tag |
| Does overexpression of PI3K confer resistance? | Overexpression cell models |
| Which genes mediate sensitivity to PI3K inhibitors? | CRISPR library screening |
| Does PI3K inhibition affect ion channel function? | Knockout of PI3K isoforms in mast cells |
How to Study the phosphatidylinositol 3-kinase inhibitor activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| In vitro PI3K kinase assay | Lipid phosphorylation | Inhibitor potency |
| Immunoblot for p-Akt | Akt activation | Cell signaling |
| Senescence-associated beta-galactosidase | Cellular senescence | Growth arrest |
| Patch-clamp electrophysiology | Ion channel activity | Mast cell function |
| Xenograft tumor growth | In vivo efficacy | Cancer therapy |
| Metabolic stability assay | Drug metabolism | Wortmannin metabolism |
| CRISPR library screen | Gene essentiality | Inhibitor sensitivity |
| Flow cytometry | Apoptosis and viability | Leukemia cell response |
Biochemical kinase assays
PI3K inhibitor activity can be measured using in vitro kinase assays that quantify phosphorylation of phosphoinositide substrates in the presence or absence of inhibitor. These assays are used to determine IC50 values and to compare potency of compounds such as wortmannin, PX-866 and ZSTK474.
Cell-based signaling readouts
Downstream effects of PI3K inhibition are commonly assessed by immunoblotting for phosphorylated Akt and its substrates. In leukemia cells, the Akt/FoxO3a/Bim axis is used as a readout of PI3K inhibitor activity. In nerve terminals, calcium-dependent Akt activation is measured to link PI3K to synaptic signaling.
Phenotypic assays
PI3K inhibitor activity is studied through phenotypic assays such as growth arrest and senescence in fibroblasts, ion channel activity in mast cells, and xenograft tumor growth in mice. These assays provide functional context for the molecular function.
Metabolism and pharmacokinetics
The metabolic stability of PI3K inhibitors can be assessed using in vitro metabolism studies, as shown for wortmannin by carbonyl reductase. Such methods help interpret inhibitor activity in vivo and guide compound optimization.
How CRISPR Can Be Used to Study GO:0141039 phosphatidylinositol 3-kinase inhibitor activity
Knockout
CRISPR knockout of PI3K isoforms or downstream effectors can mimic or modulate the effects of PI3K inhibitor activity. For example, knocking out PTEN sensitizes cells to PI3K inhibitors. Knockout of ion channel genes can test whether PI3K inhibition affects mast cell function.
Point Mutation
Point mutations in PI3K catalytic or regulatory subunits can alter inhibitor binding and sensitivity. CRISPR point-mutation models can introduce clinically relevant mutations to test resistance or hypersensitivity to inhibitors such as PX-866 or ZSTK474.
Knock-in
Knock-in of epitope tags or fluorescent reporters into PI3K genes allows visualization and quantification of inhibitor binding and downstream signaling in live cells. Tagged alleles can also be used to study protein interactions and localization.
Overexpression
Overexpression of PI3K or downstream effectors can confer resistance to PI3K inhibitors, providing a model to study the mechanisms of inhibitor activity and to identify combination strategies. Overexpression models are also useful for testing whether a gene is sufficient to drive PI3K-dependent phenotypes.
How EDITGENE Supports phosphatidylinositol 3-kinase inhibitor activity Research
Researchers studying phosphatidylinositol 3-kinase inhibitor activity-related genes often need to determine whether a candidate gene is causally involved in inhibitor response, whether a specific mutation alters sensitivity, or whether overexpression is sufficient to drive resistance. EDITGENE provides the CRISPR tools and cell models to answer these questions with rigor and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for phosphatidylinositol 3-kinase inhibitor activity research.
Frequently Asked Questions About phosphatidylinositol 3-kinase inhibitor activity
What is phosphatidylinositol 3-kinase inhibitor activity?
It is a molecular function (GO:0141039) in which a molecule binds to and decreases the activity of a phosphatidylinositol 3-kinase (PI3K).
What genes are involved in phosphatidylinositol 3-kinase inhibitor activity?
Key genes include PIK3CA, PIK3CB, PIK3CD, PIK3CG, PIK3R1, AKT1, FOXO3A, BCL2L11, EGFR and PTEN, among others.
What are examples of PI3K inhibitors?
Wortmannin, PX-866, NVP-BKM120 and ZSTK474 are well-studied PI3K inhibitors.
How does PI3K inhibitor activity affect cancer cells?
It can overcome resistance to EGFR inhibitors, block microenvironment survival signals, and induce growth arrest or apoptosis in cancer cells.
What is the role of PI3K inhibitor activity in leukemia?
In chronic lymphocytic leukemia, PI3K inhibition regulates the Akt/FoxO3a/Bim axis to overcome microenvironment-derived resistance.
Can PI3K inhibitors affect ion channels?
Yes, PI3K inhibitor activity regulates mast cell ion channel activity, linking lipid signaling to ion transport.
How is PI3K inhibitor activity measured in the lab?
It is measured using in vitro kinase assays, phospho-Akt immunoblotting, phenotypic assays and xenograft models.
What is the relationship between PI3K inhibitor activity and senescence?
A PI3K inhibitor induces a senescent-like growth arrest in human diploid fibroblasts.
Which CRISPR models are used to study PI3K inhibitor activity?
Knockout, point-mutation, knock-in and overexpression models are used to test gene function and inhibitor sensitivity.
Why is phosphatidylinositol 3-kinase inhibitor activity important for drug discovery?
It is a validated target for cancer therapy, and inhibitors such as ZSTK474 have been optimized for clinical development.
Conclusion
Phosphatidylinositol 3-kinase inhibitor activity (GO:0141039) is a well-defined molecular function that is central to PI3K signaling research and therapeutic development. Small-molecule inhibitors such as wortmannin, PX-866, NVP-BKM120 and ZSTK474 have been instrumental in revealing how PI3K inhibition affects cancer resistance, leukemia survival, ion channel function, calcium signaling and cellular senescence. By combining precise CRISPR models with biochemical and phenotypic assays, researchers can causally link genes to PI3K inhibitor responses and accelerate the translation of PI3K-targeted therapies. EDITGENE supports these efforts with custom cell models and screening services tailored to phosphatidylinositol 3-kinase inhibitor activity research.
References
- 1. Lam RS et al.. 2008. Phosphatidylinositol-3-kinase regulates mast cell ion channel activity.. Cell Physiol Biochem 22(1-4):169-76 PMID: 18769043
- 2. Tresini M et al.. 1998. A phosphatidylinositol 3-kinase inhibitor induces a senescent-like growth arrest in human diploid fibroblasts.. Cancer Res 58(1):1-4 PMID: 9426047
- 3. Ihle NT et al.. 2005. The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts.. Mol Cancer Ther 4(9):1349-57 PMID: 16170026
- 4. Rosich L et al.. 2013. The phosphatidylinositol-3-kinase inhibitor NVP-BKM120 overcomes resistance signals derived from microenvironment by regulating the Akt/FoxO3a/Bim axis in chronic lymphocytic leukemia cells.. Haematologica 98(11):1739-47 PMID: 23850807
- 5. Holleran JL et al.. 2004. In vitro metabolism of the phosphatidylinositol 3-kinase inhibitor, wortmannin, by carbonyl reductase.. Drug Metab Dispos 32(5):490-6 PMID: 15100170
- 6. Nicholson-Fish JC et al.. 2016. Phosphatidylinositol 3-Kinase Couples Localised Calcium Influx to Activation of Akt in Central Nerve Terminals.. Neurochem Res 41(3):534-43 PMID: 26198194
- 7. Giddens AC et al.. 2019. Synthesis and biological evaluation of solubilized sulfonamide analogues of the phosphatidylinositol 3-kinase inhibitor ZSTK474.. Bioorg Med Chem 27(8):1529-1545 PMID: 30850264
- 8. Kong DX et al.. 2010. ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor identified using the JFCR39 drug discovery system.. Acta Pharmacol Sin 31(9):1189-97 PMID: 20729870
